Dabur to commercialise ayurvedic drugs for malaria, diabetic treatment
19 Feb 2016
National Research Development Corporation (NRDC) today signed an agreement with Dabur India Ltd for commercialisation of two ayurvedic formulations, one for the treatment of malaria and the other for diabetes treatment.
Under the agreement, NRDC will licence Ayush-64, an ayurvedic formulation for treatment of Malaria and Ayush-82, an ayurvedic formulation for management of diabetes, both developed by Central Council for Research in Ayurvedic Sciences (CCRAS), for commercial production, marketing and distribution.
Ayush-64 has been found to be very effective for the treatment of malaria, which is one of the most prevalent, destructive widely spread diseases. The ayurvedic formulation is well known to ayurvedic physicians as `Visama Jvara' from ancient times for its wide prevalence and use against drug resistant malarial parasite.
CCRAS has developed the poly-herbal non-toxic drug after carrying out extensive pharmacological, toxicological and clinical studies, says an Ayush release.
Ayush-82, an anti-diabetic drug also developed by CCRAS, is a combination of known and tested hypoglycemic drugs.
The use of these two drugs would help millions of people suffering from malaria and diabetes, the release said.
National Research Development Corporation (NRDC) is an enterprise of the Department of Scientific and Industrial Research of the ministry of science and technology and is engaged in technology licensing, the agency has so far licensed about 10 technologies developed by CCRAS to more than 30 companies in India.